Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 143K | 8K | 0 | 0 |
| Gross Profit | 0 | 68K | 8K | 0 | 0 |
| Operating Income | -18K | -11K | -33K | -31K | -80K |
| EBITDA | -1K | -10K | 208K | -31K | -80K |
| Net Income | -1K | -16K | -20K | -31K | -80K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0105
+0.00% today
1Y Change
+337.50%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 253 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tian'an Pharmaceutical Co., Ltd. (TNPH) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and up 337.5% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow -173.6% with operating margin 0.0% and ROIC 30.8%. Valuation already assumes a fairly strong business story at P/E 1258.6. Stock Foundry combines TNPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TNPH Max Drawdown
-30.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TNPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$80.1K
-155.1% YoY
Free Cash Flow
-$78.7K
-200.2% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 143K | 8K | 0 | 0 |
| Gross Profit | 0 | 68K | 8K | 0 | 0 |
| Operating Income | -18K | -11K | -33K | -31K | -80K |
| EBITDA | -1K | -10K | 208K | -31K | -80K |
| Net Income | -1K | -16K | -20K | -31K | -80K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 143 | 3K | 2K | 107K | 15K |
| Total Assets | 6K | 360K | 7K | 396K | 21K |
| Total Liabilities | 91K | 425K | 208K | 522K | 170K |
| Shareholder Equity | -86K | -71K | -201K | -139K | -149K |
| Total Debt | 62K | 57K | 182K | 176K | 155K |
| Net Debt | 62K | 54K | 180K | 68K | 140K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
79K
-200.2% YoY
Capital Expenditures
0
Free Cash Flow
79K
-200.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-7.4%
Debt / Equity
-0.66x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.